THE WOODLANDS, Texas (February 7, 2022) – Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013, at 2:30 p.m. EST in the Conrad Room. The conference will be held at the Waldorf=Astoria Hotel in New York, NY.

A live webcast of the company presentation can be accessed via the Investor Relations section of the Company’s website at www.opexatherapeutics.com. An archive of the webcast will be available on the Company's website until May 12, 2013.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company’s leading therapy, Tcelna™, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

About The BIO CEO & Investor Conference

The 15^th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities..

For more information, please visit the Company’s website at www.opexatherapeutics.com

Contacts:
Neil K. Warma
Opexa Therapeutics, Inc.
President & CEO
281-775-0600
nwarma@opexatherapeutics.com

Investor Relations:
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com